Critical Care · 2013 · 20 citations · 0 references
PharmacyPharmacologyPharmacotherapyDrug DeliveryPulmonary Drug DeliveryRespiratory PharmacotherapyInhalation Dosage FormsInhalation Drug DeliveryInhalation TherapyMechanical VentilationNebulizer SystemsRespiratory MedicineAntimicrobial Inhalation TherapyDrug Formulation For InhalationInhalation Delivery SystemsLung Dose MeasurementMedication Delivery SystemsNebulized Aerosol FormulationsNebulized Drug FormulationsVibrating Mesh Nebulization
Amikacin Inhale (NKTR-061, BAY41-6551) is a drug-device combination in clinical development for adjunctive treatment of intubated and mechanically ventilated patients with Gram-negative pneumonia. The product uses a proprietary vibrating mesh nebulizer system (PDDS Clinical) with amikacin sulfate formulated for inhalation (3.2 ml of 125 mg/ml amikacin solution) for a 10-day twice-daily course of therapy. It is designed for use with two delivery systems: one system for intubated patients (On-vent; Figure 1 ), and a second Handheld (HH) system for patients who are extubated before completing the course of therapy (Figure 2 ). We investigated in vitro the amikacin lung dose delivered by PDDS Clinical.